135 related articles for article (PubMed ID: 38306827)
1. Chemosensitization of non-small cell lung cancer to sorafenib via non-hydroxamate s-triazinedione-based MMP-9/10 inhibitors.
Khalil HH; El-Sheshtawy MM; Khattab SN; Abu-Serie MM; Shehat MG; Teleb M; Haiba NS
Bioorg Chem; 2024 Mar; 144():107155. PubMed ID: 38306827
[TBL] [Abstract][Full Text] [Related]
2. Halting Tumor Progression via Novel Non-Hydroxamate Triazole-Based Mannich Bases MMP-2/9 Inhibitors; Design, Microwave-Assisted Synthesis, and Biological Evaluation.
Albelwi FF; Teleb M; Abu-Serie MM; Moaty MNAA; Alsubaie MS; Zakaria MA; El Kilany Y; Aouad MR; Hagar M; Rezki N
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638665
[TBL] [Abstract][Full Text] [Related]
3. Battle tactics against MMP-9; discovery of novel non-hydroxamate MMP-9 inhibitors endowed with PI3K/AKT signaling attenuation and caspase 3/7 activation via Ugi bis-amide synthesis.
Ayoup MS; Fouad MA; Abdel-Hamid H; Ramadan ES; Abu-Serie MM; Noby A; Teleb M
Eur J Med Chem; 2020 Jan; 186():111875. PubMed ID: 31740054
[TBL] [Abstract][Full Text] [Related]
4. Engineered s-Triazine-Based Dendrimer-Honokiol Conjugates as Targeted MMP-2/9 Inhibitors for Halting Hepatocellular Carcinoma.
Khalil HH; Osman HA; Teleb M; Darwish AI; Abu-Serie MM; Khattab SN; Haiba NS
ChemMedChem; 2021 Dec; 16(24):3701-3719. PubMed ID: 34547831
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of some new 1,3,4-thiadiazine-thiourea derivatives as potential antitumor agents against non-small cell lung cancer cells.
Ragab FAF; Abdel-Aziz SA; Kamel M; Ouf AMA; Allam HA
Bioorg Chem; 2019 Dec; 93():103323. PubMed ID: 31586713
[TBL] [Abstract][Full Text] [Related]
6. Targeting the interplay between MMP-2, CA II and VEGFR-2 via new sulfonamide-tethered isomeric triazole hybrids; Microwave-assisted synthesis, computational studies and evaluation.
Reda Aouad M; Almehmadi MA; Faleh Albelwi F; Teleb M; Tageldin GN; Abu-Serie MM; Hagar M; Rezki N
Bioorg Chem; 2022 Jul; 124():105816. PubMed ID: 35489270
[TBL] [Abstract][Full Text] [Related]
7. Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: Syntheses and biological assays.
Adhikari N; Halder AK; Mallick S; Saha A; Saha KD; Jha T
Bioorg Med Chem; 2016 Sep; 24(18):4291-4309. PubMed ID: 27452283
[TBL] [Abstract][Full Text] [Related]
8. Battling colorectal cancer via s-triazine-based MMP-10/13 inhibitors armed with electrophilic warheads for concomitant ferroptosis induction; the first-in-class dual-acting agents.
Morcos CA; Khattab SN; Haiba NS; Bassily RW; Abu-Serie MM; Teleb M
Bioorg Chem; 2023 Dec; 141():106839. PubMed ID: 37703744
[TBL] [Abstract][Full Text] [Related]
9. Matrix metalloproteinase-9 (MMP-9) and its inhibitors in cancer: A minireview.
Mondal S; Adhikari N; Banerjee S; Amin SA; Jha T
Eur J Med Chem; 2020 May; 194():112260. PubMed ID: 32224379
[TBL] [Abstract][Full Text] [Related]
10. Targeted Polypharmacology: Discovery of a Highly Potent Non-Hydroxamate Dual Matrix Metalloproteinase (MMP)-10/-13 Inhibitor.
Senn N; Ott M; Lanz J; Riedl R
J Med Chem; 2017 Dec; 60(23):9585-9598. PubMed ID: 28953404
[TBL] [Abstract][Full Text] [Related]
11. The inhibition of the pemetrexed-activated MAPK pathway via sorafenib is involved in the synergistic mechanism of sorafenib subsequent potentiation of pemetrexed cytotoxicity in EGFR TKI-resistant cell lines.
Jiang Y; Li C; Ma Y; Chen J; Li Y; Chen L
Clin Lab; 2012; 58(5-6):551-61. PubMed ID: 22783588
[TBL] [Abstract][Full Text] [Related]
12. [Effect of Src tyrosine kinase inhibition on secretion of MMP-2 and MMP-9 by non-small cell lung cancer cells].
Zheng R; Qin X; Li W; Kang J
Zhongguo Fei Ai Za Zhi; 2011 Jan; 14(1):13-7. PubMed ID: 21219825
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma.
Carter CA; Chen C; Brink C; Vincent P; Maxuitenko YY; Gilbert KS; Waud WR; Zhang X
Cancer Chemother Pharmacol; 2007 Feb; 59(2):183-95. PubMed ID: 16724239
[TBL] [Abstract][Full Text] [Related]
14. The novel PI3K inhibitor S1 synergizes with sorafenib in non-small cell lung cancer cells involving the Akt-S6 signaling.
Wang J; Ma S; Chen X; Zhang S; Wang Z; Mei Q
Invest New Drugs; 2019 Oct; 37(5):828-836. PubMed ID: 30456603
[TBL] [Abstract][Full Text] [Related]
15. Resveratrol inhibits human lung adenocarcinoma cell metastasis by suppressing heme oxygenase 1-mediated nuclear factor-kappaB pathway and subsequently downregulating expression of matrix metalloproteinases.
Liu PL; Tsai JR; Charles AL; Hwang JJ; Chou SH; Ping YH; Lin FY; Chen YL; Hung CY; Chen WC; Chen YH; Chong IW
Mol Nutr Food Res; 2010 Jul; 54 Suppl 2():S196-204. PubMed ID: 20461740
[TBL] [Abstract][Full Text] [Related]
16. Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.
Cabebe E; Wakelee H
Curr Treat Options Oncol; 2007 Feb; 8(1):15-27. PubMed ID: 17634832
[TBL] [Abstract][Full Text] [Related]
17. Visfatin Triggers the Cell Motility of Non-Small Cell Lung Cancer via Up-Regulation of Matrix Metalloproteinases.
Wang G; Tian W; Liu Y; Ju Y; Shen Y; Zhao S; Zhang B; Li Y
Basic Clin Pharmacol Toxicol; 2016 Dec; 119(6):548-554. PubMed ID: 27224551
[TBL] [Abstract][Full Text] [Related]
18. Halting colorectal cancer metastasis via novel dual nanomolar MMP-9/MAO-A quinoxaline-based inhibitors; design, synthesis, and evaluation.
Ayoup MS; Abu-Serie MM; Awad LF; Teleb M; Ragab HM; Amer A
Eur J Med Chem; 2021 Oct; 222():113558. PubMed ID: 34116327
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and preliminary bioactivity evaluations of 8-hydroxyquinoline derivatives as matrix metalloproteinase (MMP) inhibitors.
Chen C; Yang X; Fang H; Hou X
Eur J Med Chem; 2019 Nov; 181():111563. PubMed ID: 31415980
[TBL] [Abstract][Full Text] [Related]
20. Structure-based design and optimization of pyrimidine- and 1,2,4-triazolo[4,3-a]pyrimidine-based matrix metalloproteinase-10/13 inhibitors via Dimroth rearrangement towards targeted polypharmacology.
El Ashry ESH; Awad LF; Teleb M; Ibrahim NA; Abu-Serie MM; Abd Al Moaty MN
Bioorg Chem; 2020 Mar; 96():103616. PubMed ID: 32032847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
